BE2013C026I2 - Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer - Google Patents

Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer

Info

Publication number
BE2013C026I2
BE2013C026I2 BE2013C026C BE2013C026C BE2013C026I2 BE 2013C026 I2 BE2013C026 I2 BE 2013C026I2 BE 2013C026 C BE2013C026 C BE 2013C026C BE 2013C026 C BE2013C026 C BE 2013C026C BE 2013C026 I2 BE2013C026 I2 BE 2013C026I2
Authority
BE
Belgium
Prior art keywords
compound
compounds
euphorbia
jatrophanes
plants
Prior art date
Application number
BE2013C026C
Other languages
English (en)
Original Assignee
Leo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C026(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Laboratories Ltd filed Critical Leo Laboratories Ltd
Publication of BE2013C026I2 publication Critical patent/BE2013C026I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE2013C026C 1997-08-19 2013-04-23 Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer BE2013C026I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO8640A AUPO864097A0 (en) 1997-08-19 1997-08-19 Anti-cancer compounds

Publications (1)

Publication Number Publication Date
BE2013C026I2 true BE2013C026I2 (en) 2018-06-05

Family

ID=3802927

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C026C BE2013C026I2 (en) 1997-08-19 2013-04-23 Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer

Country Status (17)

Country Link
US (4) US6432452B1 (fr)
EP (1) EP1015413B1 (fr)
JP (3) JP2001515059A (fr)
CN (1) CN1266421B (fr)
AT (1) ATE397580T1 (fr)
AU (1) AUPO864097A0 (fr)
BE (1) BE2013C026I2 (fr)
BR (1) BR9811327A (fr)
CA (1) CA2301082C (fr)
CY (2) CY1108303T1 (fr)
DE (1) DE69839586D1 (fr)
DK (1) DK1015413T3 (fr)
ES (1) ES2308810T3 (fr)
HU (2) HU228862B1 (fr)
LU (1) LU92185I2 (fr)
PT (1) PT1015413E (fr)
WO (1) WO1999008994A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7078434B1 (en) * 1999-08-12 2006-07-18 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Use of Ginkgo extract
AU748542B2 (en) * 2000-06-07 2002-06-06 Leo Laboratories Limited Therapeutic agents - III
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US6923993B2 (en) * 2001-12-12 2005-08-02 Nicholas J. Donato Process of isolating extract from the Euphorbia obesa plant and methods for using the same
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
WO2005066151A2 (fr) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2005079471A2 (fr) * 2004-02-17 2005-09-01 University Of South Florida Compose de cytotoxine et procede d'isolement
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
DE102004044428A1 (de) * 2004-09-14 2006-03-30 Toximed Gmbh Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien
AU2005316185B2 (en) * 2004-12-13 2012-04-12 Leo Laboratories Limited Treatment of solid cancers
CA2589992C (fr) * 2004-12-13 2014-04-22 Peplin Research Pty Ltd Traitement de cancers solides
WO2006066133A2 (fr) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006134609A2 (fr) * 2005-06-16 2006-12-21 Mmi Corporation Nouvel agent anticancereux, procedes de preparation et compositions pharmaceutiques correspondantes
US7655620B2 (en) * 2005-07-07 2010-02-02 Cancure Laboratories, Llc Use of one or more metal carriers to selectively kill mammalian cells
KR20080032188A (ko) * 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
WO2007059584A1 (fr) 2005-11-25 2007-05-31 Peplin Research Pty Ltd Méthodes pour cicatriser des blessures
WO2007065925A2 (fr) * 2005-12-07 2007-06-14 Toximed Gmbh Composition pour traiter des melanomes et des impuretes de la peau, et cosmetique de soin cutane
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
EP1976835A2 (fr) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Inhibiteurs des histone desacetylases
US20080069809A1 (en) * 2006-04-20 2008-03-20 Ogbourne Steven M Compositions and methods for the diagnosis and treatment of cancer
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
DK2395993T3 (en) * 2009-02-13 2017-08-07 Leo Laboratories Ltd SKIN TREATMENT
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
PL2558435T3 (pl) 2010-04-16 2017-10-31 Leo Pharma As Krystaliczny rombowy mebutynian ingenolu
WO2011139172A1 (fr) * 2010-05-06 2011-11-10 Goran Milosavljevic Diterpènes à activité antinéoplasique et compositions pharmaceutiques les incluant
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
WO2012085189A1 (fr) 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates i
NZ612446A (en) 2010-12-22 2015-09-25 Leo Lab Ltd Ingenol-3-acylates iii and ingenol-3-carbamates
US9656945B2 (en) 2010-12-22 2017-05-23 Leo Laboratories Limited 3-acyl-ingenols II
US8858953B2 (en) 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer
WO2012176015A1 (fr) 2011-06-24 2012-12-27 Leo Pharma A/S Procédé pour le traitement de la peau endommagée par l'uv et des tumeurs du carcinome à cellules squameuses (scc) et pour l'élimination des tatouages avec le mébutate d'ingénol topique
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
WO2014001215A2 (fr) 2012-06-26 2014-01-03 Leo Laboratories Limited 3-o-hétéroaryl-ingénol
CN103655674A (zh) * 2012-09-11 2014-03-26 清华大学深圳研究生院 乳浆大戟提取物及其制备方法和应用
KR101578404B1 (ko) 2014-03-18 2015-12-18 원광대학교 산학협력단 대극속 식물 추출물 또는 분획물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN107210718A (zh) * 2014-11-20 2017-09-26 迪芬尼香港有限公司 使用多速率fir和全通iir滤波器均衡扬声器系统的声学响应的方法和装置
CN106928995A (zh) * 2015-10-01 2017-07-07 钱秀英 基于生物显色技术以服务于物联网的储物箱
CN107083236A (zh) * 2015-10-01 2017-08-22 钱秀英 一种用于判断时间的生物显色剂
US12502369B2 (en) 2015-11-11 2025-12-23 K-Gen, Inc. Methods of cancer treatment
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2017156350A1 (fr) 2016-03-09 2017-09-14 K-Gen, Inc. Méthodes de traitement du cancer
CN110023342B (zh) 2016-09-02 2022-01-11 泰国卓越科学生命中心 用于制备橡胶树胶乳提取物的方法及其组合物
CN110663685B (zh) * 2019-10-23 2021-10-12 扬州大学 一种介孔二氧化硅负载ppte的纳米农药制剂
CN112441924B (zh) * 2020-12-11 2024-05-03 浙江工业大学 巨大戟二萜化合物及其提取方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2902506A1 (de) * 1979-01-23 1980-07-24 Deutsches Krebsforsch Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel
JPS5813571A (ja) * 1981-07-14 1983-01-26 Sagami Chem Res Center ジヒドロフラン誘導体及びその製造方法
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US5886017A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. E.
US5750568A (en) 1986-06-11 1998-05-12 Procyon Pharmaceuticals, Inc. Protein kinase C Modulators. L.
IL82811A0 (en) 1986-06-11 1987-12-20 Alder Res Center Corp Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein
US5886019A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. F.
US5145842A (en) 1986-06-11 1992-09-08 Alder Research Center Limited Partnership Protein kinase c. modulators. d.
US5716968A (en) 1986-06-11 1998-02-10 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. H.
US5643948A (en) 1986-06-11 1997-07-01 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. K.
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
DE3805965A1 (de) * 1988-02-25 1989-09-07 Tamas Geb Szenasi Eszter Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
DE4102054A1 (de) 1991-01-24 1992-07-30 Geb Szenasi Tamas Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
CN1047084C (zh) 1993-03-30 1999-12-08 刘振宪 人参口服液及其制造方法
US6593371B1 (en) 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
CN1048164C (zh) 1993-08-24 2000-01-12 吴雪姣 复方菝葜口服液
JP2913451B2 (ja) 1994-06-22 1999-06-28 株式会社イナックス 防水パンの高さ調整構造
JPH08245505A (ja) 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
JPH08176002A (ja) 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
CN1070372C (zh) 1995-02-15 2001-09-05 赵国强 强力抗癌膏及其制造方法
WO1997015575A1 (fr) 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Modulateurs .y. de la proteine kinase c
CN1058620C (zh) * 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
JPH08268961A (ja) * 1996-02-28 1996-10-15 Procyon Pharmaceut Inc 抗炎症組成物
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
JP2001139468A (ja) 1999-11-11 2001-05-22 Lead Chemical Co Ltd 抗ウイルス作用を有するホルボール誘導体
US6444555B2 (en) * 1999-12-07 2002-09-03 Advanced Micro Devices, Inc. Method for establishing ultra-thin gate insulator using anneal in ammonia
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US20030185168A1 (en) * 2002-03-28 2003-10-02 Yu-Wei Tung Topology of frequency converting blocks of wireless lan access point

Also Published As

Publication number Publication date
CN1266421B (zh) 2014-06-18
CY2013020I2 (el) 2019-11-27
CY2013020I1 (el) 2019-11-27
EP1015413B1 (fr) 2008-06-04
DK1015413T3 (da) 2008-09-22
BR9811327A (pt) 2000-09-19
HUP0004262A1 (hu) 2001-08-28
PT1015413E (pt) 2008-09-15
US6787161B2 (en) 2004-09-07
CA2301082A1 (fr) 1999-02-25
JP2001515059A (ja) 2001-09-18
US20020076457A1 (en) 2002-06-20
US6432452B1 (en) 2002-08-13
EP1015413A1 (fr) 2000-07-05
US7410656B2 (en) 2008-08-12
US6844013B2 (en) 2005-01-18
AU8721798A (en) 1999-03-08
DE69839586D1 (de) 2008-07-17
LU92185I2 (fr) 2014-04-23
CN1266421A (zh) 2000-09-13
AUPO864097A0 (en) 1997-09-11
ES2308810T3 (es) 2008-12-01
CY1108303T1 (el) 2014-02-12
EP1015413A4 (fr) 2004-01-28
CA2301082C (fr) 2009-02-03
US20010051644A1 (en) 2001-12-13
WO1999008994A1 (fr) 1999-02-25
JP2015007130A (ja) 2015-01-15
JP2012031212A (ja) 2012-02-16
ATE397580T1 (de) 2008-06-15
US20050003031A1 (en) 2005-01-06
HUS1300063I1 (hu) 2019-11-28
AU736230B2 (en) 2001-07-26
HU228862B1 (en) 2013-06-28

Similar Documents

Publication Publication Date Title
BE2013C026I2 (en) Use of an ingenane compound for the manufacture of a medicament for the treatment of cancer
CA2214097A1 (fr) Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
AU7031500A (en) Therapeutic quinazoline compounds
WO2002080890A3 (fr) Composition pharmaceutique de jasmonate pour le traitement du cancer
CA2028746A1 (fr) Compositions pharmaceutiques et methodes de traitement des symptomes d'exces de table
WO2002046129A3 (fr) Inhibiteurs de l'histone deacetylase
GB2363985B (en) Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
CA2386775A1 (fr) Medicaments de traitement de tumeurs malignes
MY125150A (en) Factor vlla inhibitors
CA2108903A1 (fr) Composes dibenzoxazepine substitues, compositions pharmaceutiques et methodes d'utilisation
CA2470484A1 (fr) Combinaison comprenant de la combretastatine et des agents anticancereux
EP1118336A3 (fr) Analogues de la Somatostatine pour délivrance ciblée de médicaments anticancereux dans des cellules de cancer
EP0796622A3 (fr) Utilisation d'analogues d'hormone libérant la gonadotropine ou leurs mimes pour la préparation de compositions pharmaceutiques comme adjuvant pour le traitement invasif de carcinomes
CA2173147A1 (fr) Agent anti-obesite
GB9907571D0 (en) Compounds
EP0821969A3 (fr) Composition médicale contenant du TCF-II
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
CA2294095A1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
WO1997007136A3 (fr) Composition pharmaceutique contenant des inhibiteurs de l'inteferon gamma
AU6301094A (en) The use of compositions for combating tumour diseases
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
WO2001007029A3 (fr) Guanidines substitutees et utilisation correspondante
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
DK415185A (da) Antibiotisk aktive forbindelser, fremgangsmaade til deres fremstilling, farmaceutiske kompositioner indeholdende forbindelserne og mikroorganisme anvendelig ved forbindelsernes fremstilling
WO1998046193A3 (fr) Methode synergique de traitement du neoplasme